-
Diagnostics World News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.
May 13, 2026
-
Diagnostics World News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.
May 13, 2026
-
Diagnostics World News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence (AI) and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.
May 12, 2026
-
Diagnostics World News | There’s a seductive promise baked into the rise of large language models: that a single, powerful AI trained on the breadth of human knowledge can do virtually anything. Need to draft a contract? Summarize a research paper? Predict whether a drug molecule will cross the blood-brain barrier? Just ask GPT. But ask the executives building AI tools inside two highly specialized fields — radiology and early-stage drug discovery — and they’ll tell you that promise breaks down the moment you need answers that actually matter.
May 7, 2026
-
Diagnostics World News | There’s a seductive promise baked into the rise of large language models: that a single, powerful AI trained on the breadth of human knowledge can do virtually anything. Need to draft a contract? Summarize a research paper? Predict whether a drug molecule will cross the blood-brain barrier? Just ask GPT. But ask the executives building AI tools inside two highly specialized fields — radiology and early-stage drug discovery — and they’ll tell you that promise breaks down the moment you need answers that actually matter.
May 7, 2026
-
Diagnostics World | The diagnosis and management of hypertension is in a troublingly bleak state, despite myriad treatments and regular blood pressure checks in primary care settings intended to catch the condition early. The conundrum is rooted in a trio of problems that co-exist like “gears with broken teeth that don’t mesh together very well."
May 5, 2026
-
Diagnostics World | Alloy speeds up growth to deepen its core discovery service in antibodies, genetic medicines, and cell therapies; RyboDyn accelerates transition from foundational discovery into scaled platform execution and progresses early-stage programs into IND-enabling studies; and more.
Apr 30, 2026
-
Diagnostics World | A team of computational scientists at Lund University (Sweden) have built a deep, joint-learning proteomics model for improving the diagnostic accuracy for a handful of dementia-related conditions which in primary care settings remains challenging due to a shortage of informative biomarkers. Predicting these different but correlated pathologies together with a single blood test would facilitate a differential diagnosis with speed and confidence.
Apr 29, 2026
-
Diagnostics World | Scientists achieve world first by loading a complete genome onto a quantum computer; Cepheid and Oxford Nanopore announce an expansion of their partnership; Biognosys Group and The Michael J. Fox Foundation for Parkinson’s Research announce a collaboration; and more.
Apr 28, 2026
-
Diagnostics World | Mount Sinai Health System announced that it has adopted SOPHiA DDM, SOPHiA GENETICS’ AI-powered platform that analyzes complex genomic and multimodal data, producing real-time, actionable insights for hospital, laboratory, and biopharma institutions across the world. Mount Sinai’s molecular pathology team will use the SOPHiA DDM for Blood Cancers and SOPHiA DDM for Solid Tumors applications to enhance next-generation sequencing for blood cancers and solid tumors.
Apr 24, 2026
-
Diagnostics World | It is notoriously difficult to detect ovarian cancer early, particularly aggressive high-grade serous types that often originate as precursor lesions in the fallopian tubes. The cancer quietly spreads at a microscopic level within the abdomen, defying discovery until symptoms emerge in advanced stages of the disease when it becomes hard to treat and difficult to cure.
Apr 22, 2026